Business Updates

Q1progresspositions Abbott for accelerating growthin 2026

How tech is transforming healthcare

2025 results: Abbott achieves double-digit earnings growth

Our legacy of dividend growth continues

Putting high-risk (HR) HPV to the test: A new generation of testing

Abbott delivers strong Q3 results, reaffirms 2025 outlook

Pacing ahead: AVEIR pumps new life into CRM business

Investing in U.S. manufacturing to power health tech

Abbott's diversified healthcare leadership fuels Q2 results

Abbott Delivers Top-Tier Q1 Sales and EPS Growth

Inside Abbott’s Largest Business: Spotlight on Medical Devices

Favorable demographics propel growth in adult nutrition

Q4 Momentum Positions Abbott for Strong Growth in 2025

Abbott Increases Dividend For 53rdConsecutive Year

Abbott Opens New Facility To Meet Demand For Diabetes Technology

Can You Wear a CGM During an MRI? If It’s Ours, You Can.

Structural Heart’s Steady Beat of Innovation and Impact

Strong Performance by Abbott’s Base Business Drives Q3 Earnings

Abbott Q2: Strong Base Business Growth Continues

Innovating for a Healthier, Sustainable Future

Abbott Enters U.S. Consumer Biowearables Market With Lingo and Libre Rio

Biowearables 101: Health tech that goes deeper

Hello, Lingo: Next-gen health coach is FDA-cleared

Abbott’s Momentum Continues in First Quarter of 2024

Abbott’s TriClip Offers New Treatment Option for People With Tricuspid Regurgitation

Abbott’s Q4 Earnings Sustain Momentum Into 2024

A New Chapter in FreeStyle Libre Technology

Base Business Strength Accelerates Abbott’s Growth

Abbott Raises Dividend for 52nd Consecutive Year

Tackling Student Loans and Saving — Together

Abbott's Q3 Continues Underlying Base Business Growth Driven by Pandemic Investments

Abbott Leaders Take Center Stage at HLTH Conference

Findings from our FreeStyle Libre/GLP-1 Analysis

Base Business Powers Abbott’s Second-Quarter Results

Less is More: Abbott’s Approach to Packaging Innovation

Expanding vascular offerings to improve patient care

Abbott Delivers Q1 Results

Abbott Reaches Concussion Testing Milestone

BinaxNOW: What You Need to Know

Mind Your Melon: Get In-The-Know About Concussions

Abbott Q4 Earnings: Continued Resiliency

The Partnerships Changing How You Manage Diabetes

Meet Navitor: Key Add to Structural Heart Portfolio

Poised for Growth Amid Uncertain Environment

Abbott Announces Its New Specialty and Metabolic Powder Nutritional Manufacturing Facility Will Be in Bowling Green, Ohio

Putting You At The Center Of Your Health: Where We Are

A Better Way to Manage Diabetes, Insulin

Proclaim Plus: The Next Burst in Chronic Pain Care

Testing as a strategy to end the HIV Epidemic

Abbott’s biowearable: One sensor for glucose, ketones

FreeStyle Libre 3: Welcome to the U.S.

Let's Talk About Sex(ual Health)

Staying Ahead of COVID-19 Variants: How We're Ensuring Our Tests Keep Up

How to Make FreeStyle Libre 2 Better? Good Question.

BinaxNOW Performance, From Studies in the Field

CardioMEMS Set for Broader Use

FreeStyle Libre 2 Connected to Your Phone

Science, Real Madrid Team Up for Global Health Win

Structural Heart Portfolio Reaches New Heights

The Shortest Path: Understanding Rehydration

Our Diabetes Number: How Many People Can We Help?

The Impact of World Changing Technologies

Protecting a Healthy Environment for Us All

A Sustainable Future Starts with Health

FreeStyle Libre 3: World's Smallest Sensor is Here

COVID-19 Testing is Needed on a Mass Scale

Freestyle Libre 2: Next-Gen CGM is Here

Abbott Adds to Structural Heart Tech

Diabetes Care: More Connected Than Ever

Charting the Course for Future Innovation

FreeStyle Libre Honored by Prix Galien

Connecting Data for Better Healthcare

Leading Across Cardiovascular Health

Improving Health Through Better Data

Abbott Brings Its Proven Flu Fighters

A Better Way to Put 2 and 2 Together

Abbott Reports Full-Year 2018 Results

How Modern Healthcare Is Transforming

Rapid Diagnostics Builds for Its Future

From Start-up to Success Story

Innovating in China